Lexeo Therapeutics Acquired Mantle Therapeutics

The $8.3 million acquisition adds four Friedreich's ataxia assets to the Lexeo pipeline.

Updated on Sept. 22, 2026 in Biotech

Bold flat-color editorial illustration showing a stylized protein helix and four serum vials, representing the biotech acquisition of rare-disease assets. — Lexeo Therapeutics has acquired Mantle Therapeutics for $8.3 million, adding four Friedreich's ataxia clinical assets to its central nervous system pipeline. AI Illustration. Upload story photo >

Live Poll

Do you believe biotech firms should prioritize the development of rare disease therapies?

Lexeo Therapeutics has purchased Mantle Therapeutics for $8.3 million in an upfront cash deal. The acquisition secures four Friedreich's ataxia assets, including the clinical-stage oral therapy LX3010.

Why it matters

Lexeo aims to bolster its Friedreich's ataxia treatment platform through this acquisition and three new strategic collaborations. These assets will support the company's focus on CNS-targeted strategies and sequential dosing for the rare genetic disease.

The acquired portfolio includes LX3010, an oral combination therapy that showed a 6-point improvement in mFARS scores in early data. Friedreich's ataxia affects one in 50,000 U.S. residents, with 80% of patients developing cardiomyopathy.

The players

Lexeo Therapeutics

This is a clinical-stage genetic medicine company focused on developing therapies for cardiovascular and central nervous system diseases.

Mantle Therapeutics

This is a biotech firm that specializes in developing assets for the treatment of Friedreich's ataxia.

Weill Cornell Medicine

This is a biomedical research institution and medical school that forms strategic research partnerships with private biotech companies.

The details

Lexeo also entered into research and option agreements with Weill Cornell Medicine, Vivet Therapeutics, and Apertura Gene Therapy. The company confirmed it maintains sufficient cash runway to operate through 2028 despite a 15% staff reduction implemented in April 2025.

April 2025: Lexeo laid off 15% of its workforce.
August 2026: The company initiated a pivotal study for LX2006.
September 2026: Lexeo announced the acquisition of Mantle Therapeutics.
Early 2027: Lexeo plans to provide a program prioritization.
2027: Lexeo plans to submit an IND for an additional development candidate.

Biotech
Sept. 18
Biotech Firms Filed For Initial Public Offerings
Allergies
Sept. 18
FDA Approved Fayuvi for Sanfilippo Syndrome Type A
Biotech
Sept. 21
ADARx Pharmaceuticals Targeted $1.74 Billion IPO Valuation

The Tech Race

The acquisition expands Lexeo's portfolio beyond the clinical-stage development of LX2006, aligning with the company's broader push into rare disease treatments. This move reflects a wider trend among mid-sized biotech firms to consolidate rare disease assets to build comprehensive therapeutic pipelines.

This acquisition could eventually lead to new therapeutic options for patients living with Friedreich's ataxia. However, it does not currently change medication availability or treatment protocols for those affected by the condition.

The takeaway

Lexeo is aggressively building out its rare disease pipeline by acquiring specialized assets and forming external research partnerships. Investors and patients should monitor the 2027 data readouts as indicators of whether these new investments will yield viable medical treatments.